Antibody Based Therapy in Coronary Artery Disease and Heart Failure
DOI:
https://doi.org/10.17140/HROJ-4-140Keywords:
Monoclonal antibodies; Coronary artery disease, Atherosclerosis; Hypercholesterolaemia, Heart failure; Heart transplantAbstract
The function of the immune system is to protect the host against disease. Antibodies are a
key part of the adaptive response, recognising specific antigens and invading pathogens and
marking them for destruction or blocking their activities. A mechanistic and molecular understanding
of this process has allowed researchers to harness their natural function. They are
now routinely used as a diagnostic tool in the clinic and in research to investigate pathological
signalling. More recently, antibodies have been utilised for another application – therapy. Antibody
based therapy is one of the newest and fastest growing with nearly 70 approved drugs to
date and over 1000 in clinical trials. Investment from the pharmaceutical sector shows no signs
of abating and this technology is now widely accepted for treating cancer, autoimmune and
infectious diseases. In the context of the cardiovascular system however, antibody therapies
are relatively limited. This review summarises the monoclonal antibodies approved for clinical
use or currently in clinical trials for treating cardiovascular disorders. Presently, coronary
artery disease, heart failure and transplant are the main indications, and monoclonal antibody
therapies are discussed in the context of their specific applications.
References
Kizhedath A, Wilkinson S, Glassey J. Applicability of predic-tive toxicology methods for monoclonal antibody therapeutics: Status Quo and scope. Arch Toxicol. 2017; 91(4): 1595-1612. doi: 10.1007/s00204-016-1876-7
Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: Implications for cardiovascular dis-ease and targeting the PCSK9 pathway. Atherosclerosis. 2013; 228(1): 18-28. doi: 10.1016/j.atherosclerosis.2013.01.044
World Health Organisation (WHO). International nonpropri-etary names (INN) for biological and biotechnological substanc-es. 2016. Web site. http://www.who.int/medicines/services/inn/ BioReview2016.pdf?ua=1.
Cai HH. Therapeutic monoclonal antibodies approved by FDA in 2016. MOJ Immunol. 2017; 5(1): 00145. doi: 10.15406/ moji.2017.05.00145
Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial. JAMA. 2016; 316(22): 2373-2384. doi: 10.1001/jama.2016.16951
Ray KK, Ginsberg HN, Davidson MH, et al. Reductions in atherogenic lipids and major cardiovascular events: A pooled analysis of 10 ODYSSEY trials comparing alirocumab with control. Circulation. 2016; 134(24): 1931-1943. doi: 10.1161/ CIRCULATIONAHA.116.024604
Raedler LA. Praluent (Alirocumab): First PCSK9 inhibitor approved by the FDA for hypercholesterolemia. Am Health Drug Benefits. 2016; 9: 123-126.
White CM. Therapeutic potential and critical analysis of the PCSK9 monoclonal antibodies evolocumab and ali-rocumab. Ann Pharmacother. 2015; 49(12): 1327-1335. doi: 10.1177/1060028015608487
Food and Drug Administration (FDA). Highlights of prescrib-ing information. 2015. Web site. https://www.accessdata.fda. gov/drugsatfda_docs/label/2015/125522s000lbl.pdf.
Food and Drug Administration (FDA). Highlights of pre-scribing information. Praluent®. 2017. Web site. https://www. accessdata.fda.gov/drugsatfda_docs/label/2017/125559s001lbl. pdf.
Dewey FE, Gusarova V, Dunbar RL. Genetic and pharmaco-logic inactivation of ANGPTL3 and cardiovascular disease. New Eng J Med. In press.
Food and Drug Administration (FDA). ReoPro® Abciximab. 2013. Web site. https://www.accessdata.fda.gov/drugsatfda_ docs/label/2013/103575s5126lbl.pdf.
Reed G, Kussie P, Lee K, Zhao T, Postlethwaite A, Kang A. Inactivation of α2-antiplasmin promotes thrombus dissolu-tion in humans: Preliminary results of the novel α2-antiplasmin inactivation for Lysis of intravascular thrombi (NAIL-IT) trial. Circulation. 2016; 134(Suppl 1): A14994.
Food and Drug Administration (FDA). Highlights of pre-scribing information. 2016. Web site. https://www.accessdata. fda.gov/drugsatfda_docs/label/2016/BLA125319_858687lbl. pdf.
Abbate A, Van Tassell BW, Biondi-Zoccai GG. Blocking in-terleukin-1 as a novel therapeutic strategy for secondary preven-tion of cardiovascular events. Bio Drugs. 2012; 26(4): 217-233. doi: 10.1007/BF03261881
Ridker PM, Thuren T, Zalewski A, Libby P, On behalf of the CANTOS study group. Interleukin-1β inhibition and the pre-vention of recurrent cardiovascular events: Rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011; 162(4): 597-605. doi: 10.1016/j.ahj.2011.06.012
Stähli BE, Tardif JC, Carrier M, et al. Effects of P-selectin antagonist inclacumab in patients undergoing coronary artery bypass graft surgery: SELECT-CABG trial. J Am Coll Cardiol. 2016; 67(3): 344-346. doi: 10.1016/j.jacc.2015.10.071
Food and Drug Administration (FDA). Highlights of pre-scribing information. Actemra®. 2017. Web site. https://www. accessdata.fda.gov/drugsatfda_docs/label/2017/125276s111,12 5472s023lbl.pdf.
Kleveland O, Kunszt G, Bratlie M, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: A double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016; 37(30): 2406-2413. doi: 10.1093/eurheartj/ehw171
Holte E, Kleveland O, Ueland T, et al. Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. Heart. In press.
Mangiola M, Marrari M, Feingold B, et al. Significance of anti-HLA antibodies on adult and pediatric heart allograft out-comes. Front Immunol. 2017; 8: 4. doi: 10.3389/fimmu.2017. 00004
Colvin MM, Cook JL, Chang P, et al. Antibody-mediated rejection in cardiac transplantation: Emerging knowledge in di-agnosis and management: A scientific statement from the Ameri-can Heart Association. Circulation. 2015; 131(18): 1608-1639. doi: 10.1161/CIR.0000000000000093
Food and Drug Administration (FDA). Highlights of pre-scribing information. 2014. Web site. https://www.accessdata. fda.gov/drugsatfda_docs/label/2014/103705s5432lbl.pdf.
Food and Drug Administration (FDA). Highlights of pre-scribing information. Rituxan®. 2017. Web site. https://www. accessdata.fda.gov/drugsatfda_docs/label/2017/125166s417lbl. pdf.
Johansson S, Rosengren A, Young K, et al. Mortality and morbidity trends after the first year in survivors of acute myocar-dial infarction: A systematic review. BMC Cardiovasc Disord. 2017; 17(1): 53. doi: 10.1186/s12872-017-0482-9
Smolina K, Wright FL, Rayner M, et al. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012; 5(4): 532- 540. doi: 10.1161/CIRCOUTCOMES.111.964700
Reichert JM. Antibodies to watch in 2017. MAbs. 2017; 9(2): 167-181. doi: 10.1080/19420862.2016.1269580
Walsh G. Biopharmaceutical benchmarks. Nat Biotech. 2014; 32: 992-1000. doi: 10.1038/nbt.3040
Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. MAbs. 2016; 8(7): 1177-1194. doi: 10.1080/19420862.2016.1212149
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.